These include metal ions (e.g., Mn, Zn, Co),[30] cytosolic dsDNA,[31] DNA‐damaging agents,[32] and polymer‐based materials such as PC7A.[33] A summary of the clinical development status of all STING agonists in cancer immunotherapy is presented in Table 1. This evidence concerns the gene STING1 and cancer.